Song H, Xu M, Cai J, Chen J, Liu Y, Su Q
Chem Biomed Imaging. 2024; 1(7):628-636.
PMID: 39474138
PMC: 11504561.
DOI: 10.1021/cbmi.3c00067.
Winter R, Amghar M, Wacker A, Bakos G, Tas H, Roscher M
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204136
PMC: 11359268.
DOI: 10.3390/ph17081031.
Rahman A, Babu M, Ovi M, Zilani M, Eithu I, Chakraborty A
J Med Phys. 2024; 49(2):137-147.
PMID: 39131433
PMC: 11309130.
DOI: 10.4103/jmp.jmp_22_24.
Liu S, Li M, Liang B, Sun W, Shao Y, Hu X
Front Pharmacol. 2024; 15:1394816.
PMID: 39021831
PMC: 11252536.
DOI: 10.3389/fphar.2024.1394816.
Wacker J, Woods J, Rupert P, Peterson A, Allaire M, Lukens W
Nat Commun. 2024; 15(1):5741.
PMID: 39009580
PMC: 11251196.
DOI: 10.1038/s41467-024-50017-5.
Actinium-225 targeted alpha particle therapy for prostate cancer.
Bidkar A, Zerefa L, Yadav S, VanBrocklin H, Flavell R
Theranostics. 2024; 14(7):2969-2992.
PMID: 38773983
PMC: 11103494.
DOI: 10.7150/thno.96403.
Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets.
Taunk N, Escorcia F, Lewis J, Bodei L
Cancer J. 2024; 30(3):218-223.
PMID: 38753757
PMC: 11232930.
DOI: 10.1097/PPO.0000000000000720.
Approaches to Reducing Normal Tissue Radiation from Radiolabeled Antibodies.
Suzuki H, Kannaka K, Uehara T
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675468
PMC: 11053530.
DOI: 10.3390/ph17040508.
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review.
Gape P, Schultz M, Stasiuk G, Terry S
Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543120
PMC: 10974115.
DOI: 10.3390/ph17030334.
Development of CD46 targeted alpha theranostics in prostate cancer using Ce/Ac-Macropa-PEG-YS5.
Bobba K, Bidkar A, Wadhwa A, Meher N, Drona S, Sorlin A
Theranostics. 2024; 14(4):1344-1360.
PMID: 38389832
PMC: 10879874.
DOI: 10.7150/thno.92742.
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives.
Hooijman E, Radchenko V, Ling S, Konijnenberg M, Brabander T, Koolen S
EJNMMI Radiopharm Chem. 2024; 9(1):9.
PMID: 38319526
PMC: 10847084.
DOI: 10.1186/s41181-024-00239-1.
Alpha-Emitting Radionuclides: Current Status and Future Perspectives.
Miederer M, Benesova-Schafer M, Mamat C, Kastner D, Pretze M, Michler E
Pharmaceuticals (Basel). 2024; 17(1).
PMID: 38256909
PMC: 10821197.
DOI: 10.3390/ph17010076.
Structure and bonding of a radium coordination compound in the solid state.
White F, Thiele N, Simms M, Cary S
Nat Chem. 2023; 16(2):168-172.
PMID: 37945833
DOI: 10.1038/s41557-023-01366-z.
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of Ac-J591.
Tagawa S, Thomas C, Sartor A, Sun M, Stangl-Kremser J, Bissassar M
J Clin Oncol. 2023; 42(7):842-851.
PMID: 37922438
PMC: 10906595.
DOI: 10.1200/JCO.23.00573.
Actinium-225 Targeted Agents: Where Are We Now?.
Mourtada F, Tomiyoshi K, Sims-Mourtada J, Mukai-Sasaki Y, Yagihashi T, Namiki Y
Brachytherapy. 2023; 22(6):697-708.
PMID: 37690972
PMC: 10840862.
DOI: 10.1016/j.brachy.2023.06.228.
Development of [Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration.
Hull A, Hsieh W, Borysenko A, Tieu W, Bartholomeusz D, Bezak E
EJNMMI Radiopharm Chem. 2023; 8(1):22.
PMID: 37679594
PMC: 10484829.
DOI: 10.1186/s41181-023-00209-z.
Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies).
Hurley K, Cao M, Huang H, Wang Y
Cancers (Basel). 2023; 15(13).
PMID: 37444603
PMC: 10340719.
DOI: 10.3390/cancers15133493.
Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.
Chakraborty K, Mondal J, An J, Park J, Lee Y
Pharmaceutics. 2023; 15(3).
PMID: 36986832
PMC: 10054444.
DOI: 10.3390/pharmaceutics15030971.
Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?.
Pallares R, Abergel R
Front Med (Lausanne). 2023; 9:1020188.
PMID: 36619636
PMC: 9812962.
DOI: 10.3389/fmed.2022.1020188.
PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications.
Adnan A, Basu S
Diagnostics (Basel). 2023; 13(1).
PMID: 36611450
PMC: 9818911.
DOI: 10.3390/diagnostics13010158.